1
|
Molinaro R, Corbo C, Martinez JO, Taraballi F, Evangelopoulos M, Minardi S, Yazdi I, Zhao P, De Rosa E, Sherman M, De Vita A, Furman NT, Wang X, Parodi A, Tasciotti E. Biomimetic proteolipid vesicles for targeting inflamed tissues. Nat Mater 2016; 15:1037-46. [PMID: 27213956 PMCID: PMC5127392 DOI: 10.1038/nmat4644] [Citation(s) in RCA: 287] [Impact Index Per Article: 35.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/26/2014] [Accepted: 04/13/2016] [Indexed: 05/13/2023]
Abstract
A multitude of micro- and nanoparticles have been developed to improve the delivery of systemically administered pharmaceuticals, which are subject to a number of biological barriers that limit their optimal biodistribution. Bioinspired drug-delivery carriers formulated by bottom-up or top-down strategies have emerged as an alternative approach to evade the mononuclear phagocytic system and facilitate transport across the endothelial vessel wall. Here, we describe a method that leverages the advantages of bottom-up and top-down strategies to incorporate proteins derived from the leukocyte plasma membrane into lipid nanoparticles. The resulting proteolipid vesicles-which we refer to as leukosomes-retained the versatility and physicochemical properties typical of liposomal formulations, preferentially targeted inflamed vasculature, enabled the selective and effective delivery of dexamethasone to inflamed tissues, and reduced phlogosis in a localized model of inflammation.
Collapse
Affiliation(s)
- R. Molinaro
- Department of Regenerative Medicine, Houston Methodist Research Institute, Houston, Texas 77030, USA
| | - C. Corbo
- Department of Regenerative Medicine, Houston Methodist Research Institute, Houston, Texas 77030, USA
- EINGE–Biotecnologie Avanzate s.c.a.r.l., Via G. Salvatore 486, 80145 Naples, Italy
- IRCCS SDN, Via Gianturco 113, 80143 Naples, Italy
| | - J. O. Martinez
- Department of Regenerative Medicine, Houston Methodist Research Institute, Houston, Texas 77030, USA
| | - F. Taraballi
- Department of Regenerative Medicine, Houston Methodist Research Institute, Houston, Texas 77030, USA
- Pain Therapy Service, Fondazione IRCCS Policlinico San Matteo, Pavia 27100, Italy
| | - M. Evangelopoulos
- Department of Regenerative Medicine, Houston Methodist Research Institute, Houston, Texas 77030, USA
| | - S. Minardi
- Department of Regenerative Medicine, Houston Methodist Research Institute, Houston, Texas 77030, USA
| | - I.K. Yazdi
- Department of Regenerative Medicine, Houston Methodist Research Institute, Houston, Texas 77030, USA
| | - P. Zhao
- Department of Pathology and Genomic Medicine, Houston Methodist Research Institute, Houston, Texas 77030, USA
| | - E. De Rosa
- Department of Regenerative Medicine, Houston Methodist Research Institute, Houston, Texas 77030, USA
| | - M. Sherman
- Department of Biochemistry and Molecular Biology, Sealy Center for Structural Biology and Molecular Biophysics, University of Texas Medical Branch, Galveston, TX 77555
| | - A. De Vita
- Osteoncology and Rare Tumors Center, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy
| | - N.E. Toledano Furman
- Department of Regenerative Medicine, Houston Methodist Research Institute, Houston, Texas 77030, USA
| | - X. Wang
- Department of Regenerative Medicine, Houston Methodist Research Institute, Houston, Texas 77030, USA
| | - A. Parodi
- Department of Regenerative Medicine, Houston Methodist Research Institute, Houston, Texas 77030, USA
- IRCCS SDN, Via Gianturco 113, 80143 Naples, Italy
| | - E. Tasciotti
- Department of Regenerative Medicine, Houston Methodist Research Institute, Houston, Texas 77030, USA
- To whom correspondence should be addressed: Dr. Ennio Tasciotti, Department of Regenerative Medicine, Houston Methodist Research Institute, 6670 Bertner Ave, Houston, TX, 77030,
| |
Collapse
|